Loading...
Loading...
IDRA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 23.1M |
| Operating I/L | -22.3M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.0M |
| Pretax | -22.1M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -21.9M |
Idera Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of drugs for rare disease indications in the United States. Its flagship product, Tilsotolimod (IMO-2125), is a synthetic phosphorothioate oligonucleotide that activates the immune system by stimulating TLR9, and is used in the treatment of solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company generates revenue through the sale of its innovative drug products and has a collaboration agreement with Bristol-Meyers Squibb to further advance its research and development efforts.
